IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences (NASDAQ: IDYA) has announced the granting of non-qualified stock options to four newly hired employees through its 2023 Employment Inducement Incentive Award Plan. The Compensation Committee approved options to purchase 125,600 shares of common stock on February 27, 2025.
The stock options were granted at an exercise price of $20.24 per share, matching the closing price of IDEAYA's stock on the Nasdaq Global Select Market on the grant date. These options come with a 10-year term and follow a four-year vesting schedule: 25% vesting after the first year, with the remaining 75% vesting in equal monthly installments over the following three years. The vesting is contingent upon continued employment with IDEAYA.
IDEAYA Biosciences (NASDAQ: IDYA) ha annunciato l'assegnazione di opzioni su azioni non qualificate a quattro nuovi dipendenti attraverso il suo Piano di Incentivazione all'Occupazione 2023. Il Comitato per la Compensazione ha approvato opzioni per l'acquisto di 125.600 azioni ordinarie il 27 febbraio 2025.
Le opzioni su azioni sono state concesse a un prezzo di esercizio di $20.24 per azione, corrispondente al prezzo di chiusura delle azioni di IDEAYA sul Nasdaq Global Select Market nella data di concessione. Queste opzioni hanno un termine di 10 anni e seguono un piano di maturazione di quattro anni: il 25% matura dopo il primo anno, con il restante 75% che matura in rate mensili uguali nei successivi tre anni. La maturazione è subordinata al mantenimento dell'impiego con IDEAYA.
IDEAYA Biosciences (NASDAQ: IDYA) ha anunciado la concesión de opciones sobre acciones no calificadas a cuatro nuevos empleados a través de su Plan de Incentivo por Empleo 2023. El Comité de Compensación aprobó opciones para comprar 125,600 acciones ordinarias el 27 de febrero de 2025.
Las opciones sobre acciones se otorgaron a un precio de ejercicio de $20.24 por acción, igualando el precio de cierre de las acciones de IDEAYA en el Nasdaq Global Select Market en la fecha de concesión. Estas opciones tienen un plazo de 10 años y siguen un calendario de adquisición de cuatro años: el 25% se adquiere después del primer año, y el 75% restante se adquiere en cuotas mensuales iguales durante los tres años siguientes. La adquisición está sujeta a la continuación del empleo con IDEAYA.
IDEAYA 바이오사이언스 (NASDAQ: IDYA)는 2023 고용 유인 인센티브 수여 계획을 통해 새로 채용된 네 명의 직원에게 비자격 주식 옵션을 부여한다고 발표했습니다. 보상 위원회는 2025년 2월 27일에 125,600주를 구매할 수 있는 옵션을 승인했습니다.
주식 옵션은 부여일에 IDEAYA의 주식이 Nasdaq Global Select Market에서 마감된 가격과 일치하는 $20.24의 행사 가격으로 부여되었습니다. 이 옵션은 10년의 기간을 가지며, 4년의 취득 일정에 따라 진행됩니다: 첫 해가 지나면 25%가 취득되고, 나머지 75%는 다음 3년 동안 매달 동일한 비율로 취득됩니다. 취득은 IDEAYA와의 계속적인 고용에 따라 달라집니다.
IDEAYA Biosciences (NASDAQ: IDYA) a annoncé l'octroi d'options d'achat d'actions non qualifiées à quatre nouveaux employés dans le cadre de son Plan d'Incitation à l'Emploi 2023. Le Comité de Rémunération a approuvé des options pour l'achat de 125 600 actions ordinaires le 27 février 2025.
Les options d'achat d'actions ont été accordées à un prix d'exercice de $20.24 par action, correspondant au prix de clôture des actions d'IDEAYA sur le Nasdaq Global Select Market à la date d'octroi. Ces options ont une durée de 10 ans et suivent un calendrier d'acquisition de quatre ans : 25 % sont acquises après la première année, les 75 % restants étant acquis en versements mensuels égaux au cours des trois années suivantes. L'acquisition est conditionnée à la poursuite de l'emploi avec IDEAYA.
IDEAYA Biosciences (NASDAQ: IDYA) hat die Gewährung von nicht qualifizierten Aktienoptionen an vier neu eingestellte Mitarbeiter im Rahmen seines Anreizprogramms 2023 bekannt gegeben. Der Vergütungsausschuss genehmigte Optionen zum Kauf von 125.600 Stammaktien am 27. Februar 2025.
Die Aktienoptionen wurden zu einem Ausübungspreis von $20.24 pro Aktie gewährt, was dem Schlusskurs der IDEAYA-Aktien am Nasdaq Global Select Market am Tag der Gewährung entspricht. Diese Optionen haben eine Laufzeit von 10 Jahren und folgen einem vierjährigen Vesting-Zeitplan: 25% vesten nach dem ersten Jahr, während die verbleibenden 75% in gleichen monatlichen Raten über die folgenden drei Jahre vesten. Das Vesting ist an die Fortsetzung der Beschäftigung bei IDEAYA gebunden.
- Employee retention strategy through equity compensation
- Successful talent acquisition with 4 new hires
- Potential dilution of existing shareholders from 125,600 new stock options
The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302388197.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
What is the exercise price for IDYA's newly granted stock options in February 2025?
How many shares of IDYA stock options were granted to new employees in February 2025?
What is the vesting schedule for IDYA's February 2025 employee stock options?
How long is the term for IDYA's February 2025 employee stock options?
